Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pravastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 9/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.55 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pravastatin SCHEMBL1683285 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL13743095 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL5580577 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14627881 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL15091182 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL19993736 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL23936980 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL12567266 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL464782 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 | |
| Pravastatin SCHEMBL14621551 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1SLC22A8SLCO1B3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-2363130-A1 | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | Nycomed GmbH (DE) | 2011-09-07 | — | — | EP | claimed |
| US-20100069392-A1 | Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease | NYCOMED GMBH (DE) | 2010-03-18 | — | — | US | claimed |
| EP-2040707-A2 | COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES | Nycomed GmbH (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008003701-A2 | COMBINATION OF HMG-COA REDUCTASE INHIBITORS WITH PHOSPHODIESTERASE 4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES | NYCOMED GMBH (DE) | 2008-01-10 | — | — | WO | claimed |
| JP-11235174-A | — | — | None | — | — | JP | disclosed |
| JP-3289564-A | — | — | None | — | — | JP | disclosed |
| US-20250262268-A1 | Methods and Compositions for Inhibiting Viral Infection | NEW YORK UNIVERSITY | 2025-08-21 | — | — | US | disclosed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-118924751-B | Application of pitavastatin in preparation of medicines for reversing tumor multidrug resistance | 中国药科大学 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025092017-A1 | METHOD FOR DETECTING PRAVASTATIN-RELATED SUBSTANCE | 上海现代制药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025092016-A1 | MEASUREMENT METHOD FOR MEASURING PRAVASTATIN-RELATED SUBSTANCE | 上海现代制药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| EP-0754042-A1 | TREATMENT OF ATHEROSCLEROSIS WITH ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES | MERCK & CO. INC. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1996040863-A1 | CONVERSION OF COMPACTIN TO PRAVASTATIN BY ACTINOMADURA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040863-A1 | CONVERSION OF COMPACTIN TO PRAVASTATIN BY ACTINOMADURA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995028924-A1 | COMBINED PREPARATIONS CONTAINING A p-OXYBENZOIC ACID DERIVATIVE SUCH AS LIFIBROL AND AN HMG-CoA-REDUCTASE INHIBITOR SUCH AS LOVASTATIN, PRAVASTATIN OR SIMVASTATIN | KLINGE PHARMA GMBH (DE) | 1995-11-02 | — | — | WO | disclosed |
| WO-1994018346-A1 | CHOLESTEROL 7-ALPHA HYDROXYLASE EXPRESSION REGULATION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0459453-A3 | USE OF PRAVASTATIN FOR PREVENTING ONSET OF RESTENOSIS AFTER ANGIOPLASTY | — | 1993-02-24 | — | — | EP | disclosed |
| US-5140012-A | Administering pravastatin along with angiotensin converting enzyme inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
| JP-H03289564-A | IMMUNOASSAY OF PRAVASTATIN | SANKYO CO LTD | 1991-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | HMGCR 2256/4885SLCO1B1 4187/4885SLC22A8 4416/4885 |
| US-20100069392-A1 | Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease | HMGCR, HMGB3, PDE4A | HMGCR 1/4885SLCO1B1 2453/4885SLC22A8 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.